Dual GLP-1/GCG agonists such as mazdutide and survodutide are currently in phase 3 clinical trials as obesity treatments, with pemvidutide having recently completed phase 2 trials. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.